does blue cross blue shield cover glp-1 drugs Can employers and payers afford to drugs? Blue Cross Blue Shield to

Metabolic reprogramming in kidney diseases: evidence and therapeutic opportunities

The numerous beneficial effects of GLP-1 render this hormone an interesting candidate for the development of pharmacotherapies to treat obesity, diabetes, and neurodegenerative disorders Keywords: GLP-1, Insulin, Glucagon, Diabetes, Obesity, Incretin 1

This may include de-identified individual patient data for variables necessary to address the specific research question in an approved data-sharing request

Massarone and Vega signed on to lose weight

Given the clinical evidence reviewed above, patients with type 2 diabetes and/or obesity are the most promising candidate population to benefit from GLP-1RA-centered pharmacotherapy to improve cardiovascular and kidney outcomes